1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
To Receive Additional Development Milestone Payment from Partner
Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Announces $5 Million Share Repurchase Authorization
Investor Presentation
Reports Second Quarter 2026 Financial Results
Reg. FD, Press Release
CFO Departure - Keith Regnante Resigns; Annita Tanini Appointed Interim CFO
Appoints Anne Prener to its Board of Directors
Q2
Q1
FY 2025
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Delisting Amendment
Amended Tender Offer Statement by Issuer